Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NaPPS for knee osteoarthritis (extension after PPS-O-301)
jRCT2031250665Phase 3Recruiting
- Sponsor
- ReqMed Company, Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pentosan polysulfate sodium in osteoarthritis (OA), sponsored by ReqMed Company, Ltd. Primary endpoint: Primary: Change in WOMAC-A pain score. Started Jan 2026; status: recruiting.
02
Drugs
pentosan polysulfate sodium
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on jRCT2031250665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250665.